Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Novartis's Cosentyx Fails to Meet Primary Goal at Late-Stage Trial Provided by Dow Jones Jul 3, 2025, 5:48:00 AM. By Adam Whittaker .

TBE/iStock Editorial via Getty Images. Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach the main goal in a Phase 3 trial ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell ...